A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Inclusion Criteria:

- Asthma diagnosis for greater than equal to (>/=) 12 months prior to Visit 1

- Bronchodilator response at Visit 1, 2, or 3

- Pre-bronchodilator FEV1 of 40 percent (%) - 80% predicted at both Visits 2 and 3

- On ICS therapy at a total daily dose of 500-2000 micrograms (mcg) of fluticasone
propionate dry powder inhaler (DPI) or equivalent for >/=6 months prior to Visit 1

- On an eligible second controller medication (long-acting beta-agonist [LABA],
leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], or
theophylline) for 6 months prior to Visit 1

- Uncontrolled asthma at Visit 1 and/or Visit 2, and at Visit 3

- Chest X-ray or computed tomography (CT) scan within 3 months prior to Visit 1 or
chest X-ray during the screening period (prior to Visit 3) confirming the absence of
other clinically significant lung disease

- Demonstrated adherence with controller medication during the screening period

Exclusion Criteria:

- History of severe allergic reaction or anaphylactic reaction to a biologic agent or
known hypersensitivity to any component of the lebrikizumab injection

- Maintenance oral corticosteroid therapy within 3 months of Visit 1

- Treatment with systemic (oral, intravenous [IV], or intramuscular [IM])
corticosteroids within 4 weeks prior to Visit 1 or during the screening period

- Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or
during the screening period or anticipated need for intra-articular corticosteroids
during the course of the study

- Infection requiring hospital admission for >/=24 hours or requiring treatment with IV
or IM antibiotics within 4 weeks prior to Visit 1 or during screening; Upper or lower
respiratory tract infection within 4 weeks prior to Visit 1 or during screening;
Active infection that required treatment with oral antibiotics within 2 weeks prior
to Visit 1 or during screening; Active parasitic infection or Listeria monocytogenes
infection within 6 months prior to Visit 1 or during screening

- Active tuberculosis requiring treatment within 12 months prior to Visit 1

- Known immunodeficiency, including, but not limited to, human immunodeficiency virus
(HIV) infection

- Evidence of acute or chronic hepatitis or known liver cirrhosis

- History of interstitial lung disease, chronic obstructive pulmonary disease (COPD),
or other clinically significant lung disease other than asthma

- Known current malignancy or current evaluation for potential malignancy

- Current smoker or former smoker with a history of greater than (>) 10 pack-years

- History of alcohol or drug abuse

- Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy,
including lebrikizumab

- Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5
drug half-lives prior to Visit 1 (whichever is longer) or during screening

- Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or
during screening